EPN1 and ependymoma: For instance, the efficacy of 200 kHz has been established for human glioblastoma (U87MG, LN229, A172, LN‐18, LN‐428, LN‐319, T98G and LN‐308), human ependymoma DKFZ‐EPN1, pancreatic cancer cell lines (CFPAC‐I and HPAF‐II), lewis lung carcinoma (LLC‐1) and human fibroblast; while 150 kHz is effective for human osteosarcoma (U2OS, KHOS/NP), human lung squamous cell carcinoma (H520), human hepatocellular carcinoma (HEPG2) and murine mammary carcinoma cells (4 T1).1